Biogen Newsroom

Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $255

Futu NewsJan 16 03:31

Truist Financial Maintains Biogen(BIIB.US) With Buy Rating

Futu NewsJan 15 21:32

BMO Capital Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $164

Futu NewsJan 15 20:33

Biogen's Hold Rating: Navigating Challenges in Alzheimer's Treatments and Pipeline Development

TipRanksJan 15 20:28

Wells Fargo & Co has lowered the Target Price for Bausch Health to $165.

Gelonghui FinanceJan 14 16:22

Truist Financial Maintains Biogen(BIIB.US) With Buy Rating

Futu NewsJan 13 21:35

Truist Financial Remains a Buy on Biogen (BIIB)

TipRanksJan 13 20:37

Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $165

Futu NewsJan 13 19:33

Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges

TipRanksJan 13 09:28

Biogen Analyst Ratings

BenzingaJan 10 22:11

Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $165

Futu NewsJan 10 20:31

Wells Fargo Issues a Hold Rating on Biogen (BIIB)

TipRanksJan 10 19:41

Truist has lowered the Target Price for Bogen to $220.

Gelonghui FinanceJan 9 16:38

Biogen Is Maintained at Buy by Truist Securities

Dow JonesJan 8 19:54

Biogen Analyst Ratings

BenzingaJan 8 19:45

Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $220

Futu NewsJan 8 10:31

RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $231

Futu NewsJan 7 21:35

Guggenheim Adjusts Price Target on Biogen to $190 From $245, Maintains Buy Rating

MT NewswiresJan 3 19:48

Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler

Dow JonesJan 3 00:27

Biogen Analyst Ratings

BenzingaJan 3 00:18